These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22331113)

  • 1. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
    Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
    Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
    Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
    JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm.
    Romero-Caballero MD; Miralles de Imperial-Ollero JA; Sarabia-Marín E; Villegas-Pérez MP
    Int Ophthalmol; 2023 Aug; 43(8):2731-2736. PubMed ID: 37185774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].
    Winterhoff J; Laskawi R
    HNO; 2012 Jun; 60(6):479-83. PubMed ID: 22669435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
    Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract]   [Full Text] [Related]  

  • 16. [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].
    Lasalvia CG; Pereira Lde S; da Cunha MC; Kitadai SP
    Arq Bras Oftalmol; 2006; 69(5):701-5. PubMed ID: 17187139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.